by Holly Wobma | Jul 28, 2016
The summer 2016 Olympics are rapidly approaching and I’ve already been blown away by preview clips of some of the competing athletes performing amazing (and kind of dangerous!) looking stunts. Clouding this year’s games, however, has been the Zika virus outbreak, for...
by Mark Curtis | Jun 30, 2016
Welcome to your update from the clinic for the month of May. Long-standing industry pioneer StemCells, Inc. decided to wind down its operations after a failed Phase 2 study in spinal cord injury. Aduro Biotech also saw a failure with its GVAX product in pancreatic...
by Mark Curtis | Jun 23, 2016
Welcome to your deal review for the month of May. Intellia Therapeutics went public this past month giving investors a second shot on net if they want to gain exposure to gene editing technologies. Caladrius Biosciences spun-out its cell-based immunotherapy to AiVita...
by Stacey Johnson | Jun 10, 2016
In 2002, Jennifer Molson received a stem cell transplant for her aggressive form of multiple sclerosis (MS), diagnosed six years earlier when she was 21. This unique treatment for MS – transplanting blood stem cells from a patient’s own bone marrow to replace the...
by Stacey Johnson | May 27, 2016
The subway map is a popular metaphor for showing how to get from point A to point B with many stops along the way. It can be simple, with only a few intersecting lines of tracks – Toronto’s (shockingly inadequate) two-line system comes to mind – or complicated, like...
by Paul Krzyzanowski | May 25, 2016
A few weeks ago, I came across an interesting story about a stem cell company with a peculiar patenting strategy. As I looked into it further, I realized I’d stumbled into a complicated corporate plot that became more incredible with every turn. Endonovo Therapeutics...
Comments